Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Minapharm PharmaceuticalsCAI:MIPH +0.64%49 Equity-to-Asset is 0.48 as of Dec. 2025, which is 9% above its 10-year median of 0.44. GuruFocus rates CAI:MIPH with a GF Score™ of 49/100 and a GF Value™ of E£373.79 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Minapharm Pharmaceuticals ranks worse than 67.46% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Minapharm Pharmaceuticals Equity-to-Asset Related Terms
Minapharm Pharmaceuticals Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI:MIPH vs ZTS, UTHR, VTRS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minapharm Pharmaceuticals Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Minapharm Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Minapharm Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minapharm Pharmaceuticals (CAI:MIPH) has a Equity-to-Asset of 0.48 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Minapharm Pharmaceuticals and its competitors. This is near median its historical median of 0.44. Over the past decade, Minapharm Pharmaceuticals' Equity-to-Asset has ranged from 0.36 to 0.48. According to the industry distribution chart, Minapharm Pharmaceuticals ranks #680 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 67.5%.
Is Minapharm Pharmaceuticals' Equity-to-Asset too high?
Minapharm Pharmaceuticals' current Equity-to-Asset of 0.48 is near median its 10-year median of 0.44. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 0.48. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Minapharm Pharmaceuticals' value of 0.48 is 20% below this industry median. Based on the distribution chart, Minapharm Pharmaceuticals ranks #680 out of 1008 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Minapharm Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Minapharm Pharmaceuticals ranks #680 out of 1008 companies for Equity-to-Asset. This places Minapharm Pharmaceuticals in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Minapharm Pharmaceuticals' value of 0.48 is 20% below this benchmark. Historically, Minapharm Pharmaceuticals' own Equity-to-Asset has ranged from 0.36 to 0.48 over the past decade. While the company's 10-year median is 0.44 vs. the industry median of 0.60, Minapharm Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Minapharm Pharmaceuticals's current Equity-to-Asset of 0.48 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Minapharm Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minapharm Pharmaceuticals's current Equity-to-Asset is 0.48, which is near median its own 10-year median of 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£373.79, compared to a current price of E£807.87 — trading 116.1% above its estimated fair value. The current Equity-to-Asset is 0.48, which is near median its 10-year median of 0.44 and 20% below the Drug Manufacturers industry median of 0.60. Minapharm Pharmaceuticals' overall GF Score™ is 49/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current Equity-to-Asset is 0.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued.
The current stock price of E£807.87 is trading 116.1% above its estimated GF Value™ of E£373.79.
GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CAI:MIPH:
Equity-to-Asset: 0.48 (near median its 10-year median of 0.44)
GF Value™: E£373.79 vs. price of E£807.87 (116.1% above fair value)
Industry Position: 20% below the Drug Manufacturers median (#680 of 1008)
No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
49GF Score
Get the complete analysis for CAI:MIPH
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:MIPH has been successfully added to your 
